(19)
(11) EP 2 705 057 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.09.2016 Bulletin 2016/38

(45) Mention of the grant of the patent:
03.08.2016 Bulletin 2016/31

(21) Application number: 12723733.7

(22) Date of filing: 08.05.2012
(51) International Patent Classification (IPC): 
C07K 16/22(2006.01)
 C07K 16/46(2006.01)
(86) International application number:
PCT/GB2012/051008
(87) International publication number:
WO 2012/153126 (15.11.2012 Gazette 2012/46)

(54)

THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS OF USING THE SAME

THERAPEUTISCHE IMMUNGLOBULINE FÜR HUNDE UND VERWENDUNGSVERFAHREN DAFÜR

IMMUNOGLOBULINES POUR THÉRAPIE CANINE ET LEURS PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.05.2011 US 201161483481 P
29.08.2011 GB 201114858
06.09.2011 US 201161531439 P

(43) Date of publication of application:
12.03.2014 Bulletin 2014/11

(73) Proprietor: Nexvet Australia Pty Ltd
Melbourne VIC 3000 (AU)

(72) Inventor:
  • GEARING, David
    Southbank Victoria 3006 (AU)

(74) Representative: Carr, Anne Marie 
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)


(56) References cited: : 
WO-A2-01/77332
WO-A2-2010/117448
 WO-A2-2010/110838
   
  • PRESTA ET AL: "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, 7 August 2006 (2006-08-07), pages 640-656, XP024892146, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2006.01.026 [retrieved on 2006-08-07]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).